Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Trials
Collaboration
Funding
Sbir Grant
Leuko receives $4.5M SBIR grant for blood monitoring device
By
LabPulse.com staff writers
Medtech firm Leuko has received a $4.5 million award from the U.S. National Institutes of Health National Cancer Institute to advance the development of PointCheck, its noninvasive at-home white blood cell monitoring device.
July 24, 2024
Nanopath awarded $4M in SBIR grants
By
LabPulse.com staff writers
Nanopath has announced that it has been awarded two grants worth a total of $4 million in federal funding through the Small Business Innovation Research (SBIR) program.
May 22, 2024
Day Zero Diagnostics awarded SBIR grant to develop fecal transplant safety assay
By
Matt Limb
Boston-based Day Zero Diagnostics is receiving research funding to support the development of a pharmacovigilance assay to enhance the safety and efficacy of fecal microbiota transplants (FMT) in clinical trials.
September 1, 2023
CellChorus awarded two grants to accelerate single-cell analysis platform
By
LabPulse.com staff writers
The grants will be used to accelerate the development of CellChorus’ Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) platform for single-cell analysis.
June 30, 2023
SLAS 2022: 6 tips for scientists looking to start companies
By
Leah Sherwood
1. Find the right team
February 8, 2022
BioMarker Strategies advances immunotherapy test through SBIR grant
By
LabPulse.com staff writers
The contract runs for two years and covers use of the test for predicting response to treatments given alone or in combination to patients with non-small cell lung cancer (NSCLC). This represents the second phase of immunotherapy response test development for the NCI; in the first phase, BioMarker Strategies established proof of concept. Immunotherapies have revolutionized the treatment of several cancer types, but there is a strong need for better ways of identifying patients who benefit, as the objective response rates for PD-1/PD-L1 inhibitors are low, ranging from 10% to 30%.
January 6, 2020
Startup develops POC diagnostic for tuberculosis
By
Joseph Constance
The platform is initially intended for use in South Africa. Eventually, the technology could be applied to detect other organisms responsible for conditions in other geographies.
December 8, 2019
Page 1 of 1
